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ABSTRACT
Introduction: Patients with hypertension often
require a combination of three antihypertensive
agents to achieve blood pressure control, but
very few single-pill triple combinations are
available. The aim of this study was to deter-
mine whether a single-pill triple combination of
perindopril, indapamide, and amlodipine was
as effective as a dual-pill combination of
perindopril/indapamide plus separate amlodip-
ine at reducing blood pressure in patients with
uncontrolled, essential hypertension.
Methods: This international, multicenter,
open-label, randomized controlled trial was
conducted in men or women aged C18 years old
with confirmed essential hypertension
(SBP C140 and \160 mmHg and DBP C90
and\100 mmHg), uncontrolled on maximal
dose antihypertensive monotherapy or with a
single dose of dual therapy. Patients were ran-
domly assigned to: single-pill triple combina-
tion of perindopril 5 mg/indapamide 1.25 mg/
amlodipine 5 mg (Per/Ind/Aml) or dual-pill
combination perindopril 5 mg/indapamide
1.25 mg ? amlodipine 5 mg (Per/Ind ? Aml)
once daily for 12 weeks. The primary endpoint
was change in office supine SBP and DBP from
baseline to week 12. The proportion of respon-
ders defined as those with normalized BP
(SBP\140 mmHg and DBP\90 mmHg), and/or
decrease of SBP C20 mmHg, and/or decrease of
DBP C10 mmHg at week 12 (W12) compared
with baseline was also assessed. Secondary effi-
cacy endpoints included change in office supine
SBP and DBP, response, and BP control at weeks
4 and 8. The tolerability of the treatments was
also assessed.
Results: A total of 148 patients were random-
ized: 75 to Per/Ind/Aml and 73 to Per/
Ind ? Aml. Mean supine SBP and DBP were
149.1 ± 4.7 and 94.1 ± 3.1 mmHg, respectively,
with no relevant between-group difference. At
week 12, both triple-therapy regimens were
associated with clinically significant reductions
in SBP compared with baseline (-21.5 ± 11.7
and -20.0 ± 12.9 mmHg, respectively). Reduc-
tions in office supine DBP were also clinically
significant (-15.3 ± 7.8 and -14.8 ± 9.0
mmHg, respectively). The proportion of
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treatment responders was high in both groups:
89.2 and 87.1%, respectively. The reduction in
office supine SBP/DBP was already evident at
week 4 and maintained for the duration of the
study in both groups. The majority of patients
were treatment responders at week 4 (89.2 and
82.9%, respectively) and had achieved BP con-
trol (87.8 vs. 78.6%, respectively), which was
maintained until week 12 in both treatment
groups. Both treatments were well tolerated
with no between-group differences.
Conclusions: In adult patients with uncon-
trolled essential hypertension on treat-
ment, single-pill triple-combination therapy
with Per/Ind/Aml is as effective as the same dose
dual-pill combination of Per/Ind ? Aml. Both
treatments were associated with clinically sig-
nificant BP reductions compared with baseline
and were well tolerated.Clinical trials number:
http://www.controlled-trials.com ISRCTN:






Hypertension is amajormodifiable risk factor for
cardiovascular disease and stroke and there is
global agreement among current hypertension
management guidelines that the majority of
patients with uncomplicated hypertension
should be treated to a blood pressure (BP) goal of
systolic blood pressure (SBP)\140 mmHg and
diastolic blood pressure (DBP)\90 mmHg [1–6].
Monotherapy can effectively reduce BP in
only a limited number of patients and the
majority will therefore require treatment with
two or more agents to reach target levels [7]. In a
meta-analysis of SBP reductions in 42 trials
(N = 10,698), the combination of any two med-
ications from different BP-lowering drug classes
was approximately five timesmore effective than
doubling the dose of a single drug [8].
The use of triple-combination therapy, tar-
geting three different mechanisms of arterial
hypertension pathogenesis, is becoming
increasingly used to provide optimal BP control
[8–13] with fewer dose-related adverse
effects. In addition, each agent in the combi-
nation can lessen adverse effects of other com-
ponents [14]. This may counteract the tendency
of some physicians to prescribe lower than
guideline-recommended doses of anti-hyper-
tensive drugs because of concerns over tolera-
bility, and the inevitable suboptimal dosing and
inadequate dose titration required to achieve
target BP goals [15, 16].
When triple-combination therapy is
required, the European Society of Cardiology/
European Society of Hypertension guidelines [1]
and other guidelines [3, 17–20] recommend the
use of an angiotensin-converting enzyme (ACE)
system inhibitor or angiotensin II receptor
blocker (ARB) with a calcium channel blocker
(CCB) and a diuretic as rational and effective.
One such combination is perindopril, inda-
pamide, and amlodipine. In addition to addi-
tive effects on BP control, each component of
this combination has demonstrated protection
of target organs at risk from hypertension
including the heart, renal system, brain, and
vasculature, in a wide range of patients with
hypertension. The three components are also
complementary in terms of tolerability:
perindopril reduces the peripheral edema that is
a dose-limiting side effect of CCBs [14];
amlodipine reduces ACE inhibitor-related
cough by decreasing prostaglandin synthesis
that is induced by bradykinin [21]; and inda-
pamide is a metabolically neutral diuretic [22].
Each individual component is associated with a
large evidence base of use in arterial hyperten-
sion, and single-pill combinations have also
been extensively evaluated: perindopril/inda-
pamide has shown efficacy in patients with
recurrent stroke [23], diabetes mellitus [24], and
in octogenarians with hypertension [25];
perindopril/amlodipine combination has been
studied in detail in patients with hypertension
at high cardiovascular risk [26].
Given the extensive experience with these
agents as mono and dual therapy it was
hypothesized that combining the three agents
into a single-pill would maintain the estab-
lished efficacy and safety of these agents while
reducing dosing complexity. Knowing that
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some physicians may be reluctant to prescribe
fixed-dose triple-therapy combinations due to
concerns over tolerability, the aim of the pre-
sent study was to evaluate the clinical efficacy
and safety of a triple combination of perindopril
5 mg/indapamide 1.25 mg/amlodipine 5 mg in
a single-pill versus dual-pill combination
perindopril 5 mg/indapamide 1.25 mg plus
amlodipine 5 mg over 12 weeks, in treated
patients with uncontrolled hypertension.
METHODS
Study Design
The study was an international, multicenter,
open-label, randomized controlled trial con-
ducted at 13 centers in Russia and four centers
in Serbia. The study protocol was approved by
independent Ethics Committees, in accordance
with the local regulations in each of the coun-
tries and complied with the Declaration of
Helsinki, current Good Clinical Practice guide-
lines (including source documents archiving),
and local laws and regulations (ISRCTN regis-
tration number: 16442558). All participants
provided informed consent before enrolment.
Patients were randomized 1:1 to treatment by a
computer-generated allocation schedule using a
permuted block method (with a block size of
four) by the clinical biostatistics department of
the study sponsor. Randomization was stratified
by study center.
Participants
Eligible patients were men or women of any
ethnic origin, aged C18 years old, treated with
antihypertensive monotherapy at maximal dose
or with a single dose of dual therapy other than
study treatment (perindopril or indapamide or
amlodipine), and with confirmed essential,
uncontrolled, hypertension on treatment
(SBP C140 and\160 mmHg and DBP C90
and\100 mmHg at two separate visits: selection
and inclusion). During the run-in period (1 week)
patients continued their current antihypertensive
therapy. Uncontrolled hypertension was
confirmed at the inclusion visit. Patients were
excluded if they had any contraindications to
perindopril, indapamide or amlodipine, or any of
the following conditions: complicated hyperten-
sion (known stage III or IV hypertensive retinopa-
thy); macroalbuminuria; diabetes; moderate or
severe renal failure (creatinine clearance 30–59 and
\30ml/min, respectively); known complicated
liver disease; recent disease (previous 6 months)
such as cerebrovascular disease (ischemic stroke,
cerebral hemorrhage, transient ischemic attack);
recent ventricular rhythm disorders (except iso-
lated extrasystoles); and known or suspected
symptomaticorthostatichypotension(definedasa
reduction in SBP C20 mmHg and/or in
DBP C10 mmHg from supine to standing-up,
maintained for the first 3 min of standing-up).
Intervention
At the inclusion visit, patients were randomly
assigned to one of the following treatment
groups: a single-pill triple combination of
perindopril 5 mg/indapamide 1.25 mg/am-
lodipine 5 mg (1 tablet/day orally in the morn-
ing before breakfast), or a dual-pill combination
of perindopril 5 mg/indapamide 1.25 mg ? am-
lodipine 5 mg (1 tablet each/day orally in the
morning before breakfast) (Fig. 1). Treatment
allocation was balanced, non-centralized,
non-adaptive and stratified by center. It was
performed according to the allocation list sent
to each site (blocks of size 4). The treatment
numbers were assigned in order, sequentially,
according to the list. The treatment period was
12 weeks.
Study Assessments
All office BP measurements were witnessed and
performed at each visit (weeks 0, 4, 8, 12), on
the same arm, using a validated automatic
OMRON blood pressure measurement device
(Model 705CP-II, Omron Healthcare Inc., Ver-
non Hills, IL, USA) according to ESH guidelines
[1]: BP was recorded three times at 1–2-min
intervals in the supine position after 10 min of
rest. The mean of the last two consecutive
measurements was used as the BP level at the
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study visit. Office SBP and DBP values were
measured at baseline prior to the first drug
intake and at all post-baseline visits at trough
(i.e., 24 ± 3 h after the last intake). The response
criteria were the proportion of patients with
normalized BP (SBP\140 mmHg and DBP\90
mmHg), and/or decrease of SBP C20 mmHg,
and/or decrease of DBP C10 mmHg at week 12
(W12) compared with baseline. In order to
identify orthostatic hypotension, two addi-
tional measurements of SBP and DBP in a
standing position were performed 1 and 3 min
after rising from a supine position.
Safety assessments were performed at inclu-
sion and W12 and included complete labora-
tory examinations by local laboratories: blood
biochemistry; hematology and urine check for
proteinuria. Dyslipidemia was qualified by the
investigator based on the patient’s medical
history or according to treatment or laboratory
values and coded using the MedDRA dictionary
(version 17.0). Total cholesterol was evaluated
during the study (at baseline and at study end)
and any significant abnormal value was repor-
ted as an adverse event. At W4 only creatinine,
creatinine clearance, uric acid and potassium
were assessed. Orthostatic hypotension and
heart rate were evaluated at every visit.
Statistical Methods
Descriptive statistics were provided for study
outcome and safety analyses. The full analysis
set (FAS) was used for evaluation of the primary
endpoint. Based on the intention-to-treat prin-
ciple, the FAS corresponds to randomized
patients having received at least one dose of
study treatment and having a value at baseline
and at least one post-baseline value for office
supine SBP and DBP over the W0–W12 period.
The per protocol set (PPS) corresponds to
patients from the FAS without relevant protocol
violation(s) that could have affected the evalu-
ation of supine SBP and DBP criteria.
For all primary and secondary endpoints, the
treatment effect was estimated, as well as its
accuracy: estimate of the between-group differ-
ence, standard error of the estimate, and two--
sided 95% confidence interval (CI) of the
estimate.
The primary efficacy outcome was change
from baseline to last post-baseline value in
office supine SBP and DBP over the W0–W12
period. The response to antihypertensive treat-
ment expressed as the rate of responders at last
post-baseline visit over W0–W12 period was
also assessed.
A number of secondary efficacy endpoints
were also evaluated including: change from
baseline to post-baseline value in office supine
SBP and DBP over the W0–W4 and W0–W8
periods; response to antihypertensive treatment
expressed as the rate of responders at each
post-baseline visit over the W0–W4 andW0–W8
periods; and BP control expressed as the pro-
portion of patients with BP control at
post-baseline visit over W0–W12 period and at
each post-baseline visit W4 and W8.
Fig. 1 Study design
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Compliance with Ethics Guidelines
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation (insti-
tutional and national) and with the Helsinki
Declaration of 1964, as revised in 2013.
Informed consent was obtained from all
patients for being included in the study.
RESULTS
A total of 148 patients were randomized: 75 to
the perindopril 5 mg/indapamide 1.25 mg/am-
lodipine 5 mg group (Per/Ind/Aml) and 73 to
the perindopril 5 mg/indapamide 1.25 mg ?
amlodipine 5 mg group (Per/Ind ? Aml). The
number of patients completing the study was
134: 70 (Per/Ind/Aml) and 64 (Per/Ind ? Aml).
Fourteen patients were withdrawn from the
study (five in the Per/Ind/Aml group and nine
in Per/Ind ? Aml). The main reason for with-
drawal was protocol deviation for 10 patients
(three in Per/Ind/Aml, seven in Per/Ind ? Aml).
The number of patients withdrawn due to
adverse events was low (1 patient in each
treatment group). Protocol deviations were
mainly related to timing of blood pressure
measures with no relevant between-group dif-
ferences. The trial profile is illustrated in Fig. 2.
Baseline Characteristics
Baseline characteristics are summarized in
Table 1 and no major differences were observed
between the two groups. Mean age was 56 years
and a large proportion was at least 60 years old
(44%). Just over half of the patients were
women (53%). All patients presented with
essential hypertension with an average duration
of 99 months (range 2–471 months). A family
history of hypertension was reported in 70% of
patients. Other relevant medical history inclu-
ded a higher frequency of dyslipidemia in the
Per/Ind/Aml group than in the Per/Ind ? Aml
group: 53.3 versus 43.8%. Frequent cardiovas-
cular risk factors included smoking (18%) and
alcohol consumption (24%).
At inclusion, all patients were receiving at
least one antihypertensive treatment (27.8%
monotherapy and 72.2% dual therapy). The
most common were agents acting on the
renin–angiotensin system (96%) and diuretics
(65%). Other concomitant treatments were
mainly lipid modifying agents (29%) and
antithrombotic agents (22%).
No relevant between-group differences were
observed in vital signs. Mean supine SBP and
DBP at inclusion were 149 and 94 mmHg,
respectively. Mean heart rate was 77 bpm.
Adherence
The mean treatment duration was
82.2 ± 13.8 days for the period W0–W12 in the
FAS. Mean treatment adherence was very good
at 97.6 ± 6.4%, and all patients but one had an
overall adherence between 80 and 120%. No
relevant between-group differences were
observed in adherence.
Primary Endpoints
A decrease in office supine SBP was observed in
both treatment groups for last post-baseline
value compared with baseline, even though
patients were already receiving antihyperten-
sive therapy before entry into the study
(monotherapy at maximal dose or a single dose
of dual therapy other than study treatment).
The changes were similar in both treatment
groups: -21.5 ± 11.7 mmHg in the Per/Ind/Aml
group versus -20.0 ± 12.9 mmHg in the Per/
Ind ? Aml group; mean (SE) between-group
difference in office supine SBP -1.4 (1.8)
mmHg, 95% CI [-5.1; 2.2] (Table 2) (Fig. 3).
Results for office supine DBP followed the
same trend with a decrease over time and sim-
ilar changes in both treatment groups:
-15.3 ± 7.8 mmHg in the Per/Ind/Aml group
versus -14.8 ± 9.0 mmHg in the Per/Ind ? Aml
group; mean (SE) between-group difference
-0.5 (1.3) mmHg, 95% CI [-3.1; 2.1] (Table 2)
(Fig. 3). For both office supine SBP and DBP
results for the per protocol set (PPS) were similar
to the FAS.
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A response to antihypertensive treatment at
the last post-baseline value was observed for the
majority of patients in both treatment groups,
and the frequency of responders was similar:
89.2% in the Per/Ind/Aml group versus 87.1%
in the Per/Ind ? Aml group; mean (SE)
between-group difference 2.1% (5.4), 95% CI
[-8.5; 12.6] in the FAS. A similar trend was
observed in the PPS.
Similar changes in SBP and DBP were also
observed in the two treatment groups for the
monotherapy and dual therapy subgroups
(Supplementary Tables S1 and S2).
Secondary Endpoints
For the secondary endpoints at intermediate
visits, results for the PPS were similar to the FAS
and only the latter are presented. Most of the
changes in SBP and DBP were observed by the
first visit at week 4 and maintained over the
course of the study, and were similar in both
groups (Supplementary Figures S1 A and S1B).
At W4, SBP decreased by -19.8 mmHg in the
Per/Ind/Aml group versus -19.0 mmHg in the
Per/Ind ? Aml group; mean (SE) between-group
difference -0.7 (1.6) mmHg, 95% CI [-3.9; 2.5].
For DBP, the corresponding values were -14.6
versus -14.7 mmHg, respectively; mean (SE)
between-group difference 0.04 (1.32) mmHg,
95% CI [-2.6; 2.7]. These decreases in BP were
maintained throughout the study. Accordingly,
most patients were responders from the W4
visit (89.2 versus 82.9%, respectively; mean (SE)
between-group difference 6.3% (5.8), 95% CI
[-5.0; 17.7]. At W8, the percentage of respon-
ders was 91.9% versus 92.9%, respectively;
mean (SE) between-group difference -1.0%
(4.4), 95% CI [-9.6; 7.7].
Control of supine BP (defined as SBP
\140 mmHg and DBP\90 mmHg) was reached
in most patients in both treatment groups for
the post-baseline value at W4, W8, and W12. In
the majority of patients, control of supine BP
Fig. 2 Trial proﬁle illustrating selected/included patients
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was attained at W4 and maintained until W12
in both treatment groups. At W4, 87.8% of
patients in the Per/Ind/Aml group versus 78.6%
in the Per/Ind ? Aml group achieved control of
supine BP; mean (SE) between-group difference
9.3% (6.20), 95% CI [-2.89; 21.43]. W8 values
were 85.1 versus 88.6%, respectively; mean (SE)
between-group difference -3.4% (5.62), 95% CI
[-14.45; 7.57]. W12 values were 81.1 versus
80.0%, respectively; mean (SE) between-group
difference 1.1% (6.60), 95% CI [-11.86; 14.02].
Safety
Safety was evaluated in all patients who took at
least one dose of the study drug (safety set).
Emergent adverse events (EAEs) were reported
in 18.7% patients in the Per/Ind/Aml group and
21.9% patients in the Per/Ind ? Aml group. The
most frequent EAEs in the Per/Ind/Aml group
were hypokalemia (2.7%) and nasopharyngitis
(2.7%), and in the Per/Ind ? Aml group the
most frequent EAEs were hyperuricemia, and an
increase in potassium, and blood urea (2.7%
each); none were serious. There were no reports
of peripheral edema or cough.
EAEs leading to treatment withdrawal were
reported in one patient in each treatment
group: hypertension in the Per/Ind/Aml group
and rash (considered treatment-related) in the
Per/Ind ? Aml group. Neither event was serious
and both patients recovered.
Table 1 Baseline demographic characteristics in the randomized set
Baseline characteristic Per/Ind/Aml (n5 75) Per/Ind1 Aml (n5 73) Global (n5 148)
Age (years) 57.2 ± 10.6 55.6 ± 10.9 56.4 ± 10.8
Over 60 years (%) 46.7 41.1 43.9
Women (%) 53.3 52.1 52.7
BMI (kg/m2) 27.8 ± 3.3 27.9 ± 2.9 27.8 ± 3.1
Duration of hypertension (months) 103.5 ± 89.7 94.1 ± 78.7 98.9 ± 84.3
Family history of hypertension (%) 68.0 72.6 70.3
Dyslipidemia (%) 53.3 43.8 48.7
Smoker (%) 18.7 17.8 18.2
Alcohol consumption (%) 26.7 20.6 23.7
Previous treatment for hypertension (%)
Monotherapy (%) 31.1 24.3 27.8
Bi-therapy (%) 68.9 75.7 72.2
Agents involved (%)
ACEI or ARB 93.3 98.6 95.9
Diuretic 61.3 68.5 64.9
CCB 14.7 9.6 12.2
Concomitant treatment
Lipid modifying agents 32.0 26.0 29.1
Antithrombotic agents 22.7 21.9 22.3
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In this study, patients were carefully fol-
lowed for any signs of emergent hypotension
and orthostatic hypotension. Only one patient
reported an emergent hypotension in the Per/
Ind ? Aml group. This EAE was not serious and
was not considered treatment-related. None of
the patients were affected by a symptomatic
orthostatic hypotension.
Treatment-related EAEs were reported in
only a few patients: (4.0%) in the Per/Ind/Aml
group and (6.8%) in the Per/Ind ? Aml group.
Those that were reported were in accordance
with those listed in the summary of product
characteristics for perindopril, indapamide, and
amlodipine.
Blood biochemistry results showed that the
rate of patients affected by potentially clinically
significant abnormal (PCSA) values was low in
both treatments groups (\5%) and mostly
detected for creatinine clearance (low value,
whatever the formula used) in (4.2%) patients
in the Per/Ind/Aml group and (4.4%) patients in
the Per/Ind ? Aml group. However, all these
patients already had a baseline creatinine
clearance\90 ml/min or ml/min/1.73 m2 and
were aged C60 years except for one patient aged
less than 60 years in the Per/Ind ? Aml group.
DISCUSSION
As expected, this study confirms the similar and
clinically significant efficacy in reducing office
supine BP of both regimens with reductions of
21.5 and 20.0 mmHg (SBP) and 15.3 and 14.8
(DBP) for the Per/Ind/Aml and Per/Ind ? Aml
groups, respectively. These reductions were
achieved in a population with treated hyper-
tension remaining uncontrolled on maximal
dose monotherapy or single-dose dual therapy
(mean baseline 149.1/94.1 mmHg), and both
treatment groups used low doses of the active
components (perindopril 5 mg, indapamide
1.25 mg, amlodipine 5 mg). The majority of
patients were responders: 89.2% (Per/Ind/Aml)
and 87.1% (Per/Ind ? Aml). The results indicate
that therapy with therapeutic doses of three
component antihypertensive therapies: ACE
inhibitor (perindopril), CCB (amlodipine) and
diuretic (indapamide) allows BP targets to be
achieved in eight out of ten patients previously
uncontrolled on mono or dual therapy.
Analysis of the secondary endpoints revealed
that achievement of BP control was rapid. The
full effect on supine SBP and DBP was attained
by W4 and then maintained until the end of the
Table 2 Change in ofﬁce supine blood pressure from baseline to week 12
Per/Ind/Aml (n5 74) Per/Ind1 Aml (n5 70)
SBP (mm Hg)
Baseline (mean ± SD) 149.1 ± 4.9 (95% CI [147.9; 150.1]) 149.0 ± 4.7 (95% CI [147.9; 150.1])
Week 12 127.6 ± 11.1 (95% CI [125.0; 130.1]) 129.0 ± 11.7 (95% CI [126.2; 131.8])
Week 12-baseline -21.5 ± 11.7 (95% CI [-24.3; -18.8]) -20.0 ± 12.9 (95% CI [-23.1; -17.0])
Estimatea ± SD -1.4 ± 1.8 (95% CI [-5.1; 2.2])
DBP (mm Hg)
Baseline (mean ± SD) 94.1 ± 3.0 (95% CI [93.4; 94.8]) 94.1 ± 3.1 (95% CI [93.4; 94.9])
Week 12 78.8 ± 8.0 (95% CI [76.9; 80.6]) 79.3 ± 8.4 (95% CI [77.3; 81.3])
Week 12-baseline -15.3 ± 7.8 (95% CI [-17.1; -13.5]) -14.8 ± 9.0 (95% CI [-17.0; -12.7])
Estimatea ± SD -0.5 ± 1.3 (95% CI [-3.1; 2.0])
Comparison between groups during the study period (week 12-baseline) for the full analysis set (n = 144)
Aml amlodipine, CI conﬁdence interval, Per perindopril, Ind indapamide, SD standard deviation
a Estimate (±standard deviation) of the difference in adjusted mean changes from baseline to last post-baseline value until
week 12 [Per/Ind/Aml]-[Per/Ind ? Aml] using a general linear model with treatment, baseline, and center as covariates
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study. The percentage of responders was already
very high at W4, with a rate of 89% in the Per/
Ind/Aml group compared with 83% in the Per/
Ind ? Aml group, and more importantly the
rate of hypertension control was 88 versus 79%,
respectively. Rapid attainment of target BP
levels is an important goal of therapy and can
lead to improved cardiovascular outcomes. Re-
sults from several major cardiovascular clinical
trials suggest that the risk of vascular events is
significantly influenced by the time it takes to
achieve BP control [26–29].
Both triple-therapy regimens showed good
tolerability and safety in the current study. The
adverse events reported were in accordance
with the known safety profile of the compo-
nent drugs (perindopril, indapamide and
amlodipine). Importantly there was no
increased risk of hypotension with the use of
triple therapy and no report of any peripheral
edema or cough.
The study confirms previous observations
from the PIANIST study [22] conducted in a
high-risk population, in whom target BP levels
were also achieved in more than 80% patients
who had previously taken two antihypertensive
drug combinations, albeit at higher doses of the
three components than in the present study.
The results suggest that the triple-therapy Per/
Ind/Aml combination is suitable for a wide
spectrum of patients with hypertension at both
low and high cardiovascular risk.
Neither the present study nor the PIANIST
trial was designed to evaluate long-term out-
comes. However, a post hoc analysis of data
from ADVANCE (Action in Diabetes and Vas-
cular Disease: Preterax and Diamicron Con-
trolled Evaluation) hints at possible advantages
of a triple combination. In the blood pressure
arm of ADVANCE, 11, 140 patients with type 2
diabetes were randomly assigned to a fixed
combination of perindopril/indapamide (4/
1.25 mg) or placebo. Of these, 3427 patients
were also receiving a CCB at baseline [30].
Active treatment reduced the relative risk of
death by 28% (95% CI [10%; 43%]) among
patients with CCB at baseline compared with
5% (-12 to 20%) among those without CCB
(P homogeneity = 0.02). The relative risk
reduction for major cardiovascular events was
12% (-8 to 28%) versus 6% (-10 to 19%) for
those with and without CCB at baseline
although the difference was not statistically
significant (P homogeneity = 0.38). The benefit
on total and cardiovascular death was seen
independent of BP reduction because the group
on CCBs had a 4.7 mm Hg SBP reduction,
whereas the non-CCB group had a 6.2 mm Hg
reduction. The treatment benefits were
observed despite a higher risk profile among the
patients receiving CCB, including a longer
duration of type 2 diabetes, more elevated SBP
and DBP, higher rates of antihypertensive drug
treatment, and higher rates of previous cardio-
vascular disease. There was no detectable in-
crease in adverse effects in those receiving a
CCB.
The greater BP reductions achieved with
antihypertensive drug combinations means
Fig. 3 Change in ofﬁce supine blood pressure from
baseline to week 12 with triple-drug antihypertensive
therapy containing perindopril, indapamide, and amlodip-
ine in patients with uncontrolled hypertension (SBP C140
and\160 mmHg and DBP C90 and\100 mmHg at two
separate visits: selection and inclusion). Comparison
between single-pill (Per/Ind/Aml, n = 74) and dual-pill
combinations (Per/Ind ? Aml, n = 70). Aml amlodipine,
Per perindopril, Ind indapamide
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that lower drug doses are required to reach BP
goals with subsequent minimized adverse
effects. Furthermore, one component of an
antihypertensive combination therapy can
reduce the occurrence of adverse events caused
by a second component with a different mech-
anism of action. For example, thiazide diuretics
lower BP by reducing volume, which may acti-
vate the renin–angiotensin–aldosterone system
(RAAS) as a compensatory mechanism and in
turn raise BP; a RAAS blocker counteracts this
effect and provides additive BP control. RAAS
blockers may also reduce the risk of CCB-in-
duced edema by beneficial effects on post-cap-
illary dilation and hydrostatic pressure [31].
There are currently two other approved sin-
gle-pill triple-therapy combinations available
in Europe: olmesartan/amlodipine/hydro-
chlorothiazide [32] and valsartan/amlodipine/
hydrochlorothiazide [33]. However, these
agents have no long-term outcome data and
neither contains a diuretic that has proven
efficacy in a clinical outcome trial, such as
indapamide [23, 25, 30] which is recommended
by cardiology experts because of its strong
morbidity and mortality data [34–38]. As the
first single-pill triple-therapy combination
incorporating an ACE inhibitor, Per/Ind/Aml
fulfills a therapeutic need for many patients
currently benefiting from an ACE-inhibitor
based therapy who require an additional ther-
apy with single pill. Clinically, ACE inhibitors
and ARBs may appear similar. Both are used to
treat cardiovascular risk factors and both reduce
BP, stroke and symptoms of heart failure.
However, the existence of clinical differences,
in particular with regards to cardiovascular risk
reduction, have been demonstrated by a num-
ber of authors. Recently, several meta-analyses
have compared the effects of ACE inhibitors and
ARBs demonstrating that ACE inhibitors pre-
vent coronary events with reductions in car-
diovascular morbidity and mortality endpoints
while ARBs are, at best, efficient for the pre-
vention of stroke [39]. One of these, which was
fundamentally robust in terms of data quality
and numbers analyzed (73,100 patients),
showed that ACE inhibitors, but not ARBs, were
associated with mortality reduction [40]. This
finding was confirmed in a further
meta-analysis, performed in 108,212
patients without heart failure, but at high car-
diovascular risk [41]. Parallel meta-analyses of
ACE inhibitor and ARB trials vs. placebo or
other active comparator, and meta-regression
analyses that have adjusted for BP within the
trials, have demonstrated that ACE inhibitors
reduce the risk of myocardial infarction and
mortality above and independently of BP low-
ering, whereas ARBs do not, reinforcing the
need for an ACE inhibitor in a triple-therapy
combination [42]. The meta-analysis of Ferrari
et al. showed that perindopril-based trials
accounted for a substantial part of the all-cause
and cardiovascular mortality reduction
observed with RAAS inhibitors in hypertension
[39].
A further benefit of a single-pill triple
combination is that it reduces the complexity
of the treatment regimen. The use of sin-
gle-pill combinations has been shown to
markedly improve patient adherence [43–45].
Improved adherence is associated with greater
BP control [46, 47] and reduced cardiovascular
events [48]. People with hypertension often
suffer other comorbid conditions that may
necessitate taking multiple medications.
Healthcare providers and patients may there-
fore be less willing to accept additional pills to
treat one condition or to increase the dose of a
single agent because of concerns about
increased side-effects. Single-pill triple-com-
bination therapy can help overcome this
clinical inertia by reducing dosing complexity
at the same time as improving efficacy and
tolerability [49–51].
Limitations
Our study is subject to potential limitations.
While randomized, the study was not con-
ducted double blind according to the purpose of
the study and its exploratory nature which
compared fixed versus free combination regi-
mens on a limited number of patients, conse-
quently, no sample size calculation was
performed and no formal power calculation
were made. The type I error for statistical anal-
yses was set at a = 5% using a two-tailed test and
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no interpretation of statistical tests was pro-
vided. Due to the design of such randomized
clinical trials, the enhanced compliance/adher-
ence to treatment that would be expected with
fixed combination cannot be determined; only
a clinical study conducted in daily medical
practice could address this issue. However,
control of hypertension was demonstrated from
the week 4 visit in 88% of patients on the sin-
gle-pill triple-drug combination compared with
79% on dual therapy ? amlodipine. Finally,
only the lowest dose of this fixed combination
was evaluated (Per/Ind/Aml 5/1.25/5 mg). Two
higher, single-pill, triple-therapy dosages (10/
2.5/5 and 10/2.5/10 mg) are also available on
the market.
CONCLUSIONS
In patients with uncontrolled essential hyper-
tension, single-pill triple therapy with perindo-
pril 5 mg/indapamide 1.25 mg/amlodipine
5 mg was as effective as the same dose of a
dual-pill combination of perindopril/inda-
pamide plus separate amlodipine with earlier
achievement of BP control.
Both dosing regimens produced clinically
significant reductions in SBP and DBP at
1 month which were maintained until the
end of the study. The majority of patients in
both treatment groups responded early to
the antihypertensive therapy and achieved
BP control. Both treatment regimens were
well tolerated.
Until now, the only choice for physicians
wanting to initiate single-pill triple combina-
tions was an ARB-based therapy [1, 2, 6].
Patients already treated with an ACE inhibi-
tor-based dual therapy who required three drugs
in a single-pill were obliged to switch to other
therapeutic classes. Perindopril/indapamide/
amlodipine is currently the only triple-drug
therapy incorporating an ACE inhibitor in a
single pill, providing an evidence-based drug
combination supported by international guide-
lines and recommendations for the treatment of
hypertension.
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